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ABSTRACT 
Background: Photodynamic Therapy (PDT) is an attractive modality for treating 
solid cancers. This study evaluates the efficacy of Hypericin-PDT as a cytotoxic 
therapy in colorectal cancer (CRC), using 2D cell cultures and 3D multicellular 
tumour spheroids. 
 
Methods: Spheroids were generated through forced-floating and agitation-based 
techniques. 2D and spheroid models of HT29 and HCT116 CRC cells were 
incubated with Hypericin (0–200nM) for 16 hours. Cultures were irradiated with 
light (1J/cm2) and cytotoxicity assessed using Propidium Iodide fluorescence. 
Expression of ABCG2 protein was assessed by immunoassays in 2D and spheroid 
cultures. The effect of ABCG2 inhibition, using 10μM Ko143, on cytotoxicity 
following Hypericin-PDT was evaluated. 
 
Results: Hypericin-PDT produced a significant reduction in HT29 (p<0.0001) and 
HCT116 (p<0.0001) cell viability in 2D cultures, with negligible non-phototoxicity. 
Spheroids were more resistant than 2D cultures to Hypericin-PDT (HT29: p=0.003, 
HCT116: p=0.006) and had a greater expression of ABCG2. Inhibition of ABCG2 in 
spheroids with Ko143 resulted in an enhanced Hypericin-PDT effect compared to 
Hypericin-PDT alone (HT29: p=0.04, HCT116: p=0.01). 
 
Conclusions: Hypericin-PDT has reduced efficacy in CRC spheroids as compared 
to 2D cultures, which maybe attributable through upregulation in ABCG2. The 
clinical efficacy of Hypericin-PDT maybe enhanced by ABCG2 inhibition. 
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INTRODUCTION 
 
Photodynamic Therapy (PDT) involves the administration of a tumour-
retaining photosensitiser (PS), followed by light administration to generate reactive 
oxygen species (ROS) that cause necrosis and apoptosis, depending on the type 
and concentration of PS, light dose and tissue sensitivity [1–3]. Hypericin, a 
photoactive compound found in St. John’s Wort (Hypericum perforatum) [4], has 
attracted interest through its diverse range of medicinal applications, including PDT 
in pre-clinical cancer studies [5–12]. Hypericin possesses several advantages over 
other photosensitisers, including a wide light absorption spectrum, low 
photobleaching, high quantum yield and negligible non-phototoxicity [8,13–15]. 
 
Pre-clinical evaluation of anti-cancer therapeutics has traditionally used 
two-dimensional (2D) monolayer cancer cell cultures, which are simple and 
reliable. However, they fail to replicate the diversity and complexity of in vivo 
cancers [16,17]. Solid tumours exhibit heterogeneity in access to oxygen, nutrients 
and essential growth factors leading to diversity in intra-tumoural cellular 
proliferation, survival and response to anti-cancer treatment [18], which cannot be 
reproduced in 2D cell cultures [19,20]. Three-dimensional (3D) multicellular tumour 
spheroids simulate a more realistic in vivo cancer model [21] incorporating the 
cellular interactions that are crucial to signalling pathways, and the heterogeneous 
distribution of oxygen and metabolites that influence proliferation and survival 
[22,23]. Spheroids also provide useful information on the spatiotemporal 
distribution and pharmacokinetics of anti-cancer drugs [24]. 
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Chemotherapy is routinely given post-operatively to colorectal cancer 
(CRC) patients at high-risk of recurrence, but with a survival advantage of only 
10% [25,26]. Alternative treatment strategies are therefore required to improve 
outcomes. PDT is one such strategy, supported by clinical evidence of efficacy: the 
outcome for patients with lung [27] and bladder [28] cancers has been shown to be 
improved by the addition of PDT as compared to surgery alone. PDT also has a 
role in palliation and does not interact with other adjuvant therapy [29]. 
 
The aim of the current investigation is to compare the efficacy of Hypericin-
PDT in 2D and spheroid CRC cultures and to explain any differences observed in 
terms of the cellular characteristics of the two models. 
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MATERIALS AND METHODS 
 
Materials 
Hypericin was obtained from Molecular Probes® by Life TechnologiesTM 
(Eugene, Oregon, USA) and prepared as a 100μM stock solution in ethanol. 1mL 
aliquots of the stock solution was stored in the dark. Ko143 hydrate, an inhibitor 
of ABCG2, was purchased from Sigma Aldrich (Gillingham, UK) and was 
prepared as a 1mg/mL stock solution in DMSO and stored as 100μL aliquots. 
 
Cell line and culturing conditions 
Human colon cancer cell lines, HCT116 and HT29, were obtained from 
the European Collection of Authenticated Cell Cultures (Salisbury, UK). Both cell 
lines were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium plus 
GlutaMAXTM (Gibco® by Life TechnologiesTM, Paisley, UK) supplemented with 
10% (v/v) Fetal Bovine Serum (FBS) (Sigma-Aldrich). Cell cultures were 
maintained at 37°C/5% CO2/95% relative humidity. Upon 80-90% confluency, 
cell cultures were washed with Dulbecco’s Phosphate-Buffered Saline (DPBS, 
Gibco® by Life TechnologiesTM) and incubated for 5 minutes with 0.05% (v/v) 
trypsin and 0.5% (v/v) ethylenediaminetetraacetic acid (EDTA, Gibco® by Life 
TechnologiesTM) in DPBS. Cell medium containing 10% (v/v) FBS was added to 
trypsinised cells and the cell suspensions centrifuged at 400g for 5 minutes. The 
supernatant was discarded and the pelleted cells resuspended in fresh medium, 
seeded into 75cm2 tissue culture flasks (Corning Inc., New York, USA) and 
grown to 80-90% confluence for the experiments. 
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Photodynamic therapy 
For 2D cell cultures, 5x104 cells were seeded per well into 96-well tissue 
culture plates (Corning Inc.) and incubated at 37°C/5% CO2/95% for 24 hours. 
For spheroid cultures, agarose powder (Sigma-Aldrich) was dissolved into 
deionised water to make a 1% solution. 50μL of the agarose solution was added 
into each well of a 96-well plate, and left at room temperature for 20 minutes to 
gel. 500 cells were then added to each well and the plate centrifuged at 360g for 
10 minutes and incubated at 37°C/5% CO2/95% for 48 hours. Cell cultures were 
treated with (0-200nM) Hypericin in the dark for 16 hours before being washed 
with DPBS. Phenol red-free RPMI 1640 medium with L-glutamine (Gibco® by Life 
TechnologiesTM) supplemented with 10% (v/v) FBS was added to cultures. 
Depending on the experimental conditions, cultures were either irradiated with 
light or kept in the dark at room temperature. 
 
Light treatment 
 Cell culture plates were placed on top of the diffuser surface of a light-
radiating device and treated with a light dose of 1J/cm2. Light treatment lasted for 
72 minutes and 28 seconds at 0.23mW/cm2. The light-radiating device comprised 
of a series of LED’s (one hundred and ninety-two HLMP-EL3B-WXKDD Amber 
LEDs (Avago Technologies, California, USA), with peak wavelength of 594nm 
and a spectral half-width of 13nm, and an internal fan to prevent overheating. 
 
Inhibiting ABCG2 
 Cell cultures were incubated with 10μM Ko143 at 37°C/5% CO2/95% for 90 
minutes followed by the addition of increasing doses of Hypericin (0 – 200nM) for 
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an additional 16 hours. Cultures were then washed and treated with light as 
described above. 
 
Assessing Cell Viability 
 Quantifying cytotoxicity: Twenty-four hours following irradiation, 2D and 
spheroid cultures were treated with 1.3μg/mL propidium iodide (Biotium Inc., 
California, USA) for 15 minutes. Cell cultures were then washed twice with DPBS 
and fresh cell culture medium added. Fluorescence was measured on a Mithras 
LB 940 Microplate Reader (Ex: 540nm, Em: 620nm) (Berthold Technologies Ltd., 
Harpenden, UK). 
 Visualising cytotoxicity: Twenty-four hours following irradiation, spheroid 
cultures were incubated with 1.3μg/mL propidium iodide (excitation: 530nm, 
emission: 620nm, exposure time: 500ms) and 5μg/mL Hoechst 33342 (excitation: 
350nm, emission: 450nm, exposure time: 500ms) (Life TechnologiesTM) 
simultaneously for 15 and 60 minutes respectively. spheroids were then washed 
and fluorescence visualised using the EVOS™ FL Imaging System (Life 
TechnologiesTM).  
 
Spinner flask spheroid culture 
 Cells were washed and trypsinised and the cell suspensions transferred 
into CELLSPIN Stirrer spinner flasks (INTEGRA Biosciences Corp., New 
Hampshire, USA), where they were maintained in cell culture medium with 
constant agitation at 75 rpm on a stirring platform and incubated at 37°C/5% 
CO2/95%. Cell culture media was changed every 3 days. Fifteen to twenty day 
old spheroids were used for experiments. 
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Immunofluorescence staining 
Spinner flask spheroids were embedded into Cryo-M-bed (Bright 
Instruments, Luton, UK) and sections (5µm) were cut onto glass slides using a 
Leica CM3050 S Research Cryostat (Leica Microsystems (UK) Ltd, Milton 
Keynes, UK). 2D cultures were grown to confluency on glass coverslips. 
Spheroid sections and 2D cultures were fixed with 4% PFA, blocked with 0.5% 
skimmed milk and incubated with anti-BCRP antibody (1:20, BXP-21) (Millipore, 
Watford, UK) for 1 hour at room temperature. They were then washed with PBS 
and incubated with an Alexa Fluor 488-conjugated secondary antibody (1:300) 
(Life TechnologiesTM) for 30 minutes at room temperature. Slides and coverslips 
were washed and mounted using ProLong™ Gold Antifade Mountant with DAPI 
(Life TechnologiesTM). Slides were imaged using the Zeiss Axio Imager Z1 (Carl 
Zeiss Ltd, Cambridge, UK). 
 
Protein extraction and Western blotting 
 Spinner flask spheroids were washed with ice-cold DPBS and sonicated in 
RIPA buffer with protease inhibitor for 15 minutes. Similarly, 2D cultures were 
grown to confluency in a 75cm2 cell-culturing flask, washed with ice-cold DPBS, 
and lysed in RIPA buffer with protease inhibitor for 15 minutes. Lysed cells were 
centrifuged at 14,000 rpm for 10 minutes and the supernatant was aliquoted and 
stored at -80°C. Protein concentration was determined using the DC™ Protein 
Assay kit (Bio-Rad, Watford, UK). Lysates were resolved using LDS-PAGE and 
blotted onto a PVDF Transfer Membrane (Thermo Fisher Scientific, Altrincham, 
UK). The membranes were blocked with 5% skimmed milk for 30 minutes, 
followed by further blocking with 1% skimmed milk for an additional 30 minutes. 
The membranes were incubated overnight at 4°C with an anti-BCRP antibody 
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(1:200, BXP-21) (Millipore, Watford, UK). The membranes were then incubated 
with a horseradish peroxidase-conjugated secondary antibody for 1 hour at room 
temperature prior to developing bands using the SuperSignal™ West Femto 
Maximum Sensitivity Substrate (Thermo Fisher Scientific) and imaged on the 
ChemiDoc™ XRS+ System (Bio-Rad). β-actin served as a loading control. 
 
Uptake of Hypericin in spheroids 
 Spinner flask spheroids were treated with 200nM Hypericin for 16 hours, 
embedded, sectioned onto slides and mounted as described above. Slides were 
imaged on the Nikon A1R Confocal Microscope (Nikon UK Ltd, Kingston upon 
Thames, UK). 
 
Prolonged culture of spheroids following Ko143 treatment and Hypericin-
PDT 
Spheroids were grown in agarose-coated plates, then subjected to Ko143 
incubation and Hypericin-PDT as described above. Spheroids were cultured for 
an additional 10 days with cell culture media changed every day. 
Transillumination images of spheroids were taken using the EVOS™ FL Imaging 
System. Volumes of spheroids were calculated using ImageJ (National Institutes 
of Health, Maryland, USA). 
 
Statistical Analysis 
 One-way ANOVA and Student’s t-test were used to perform statistical 
analysis using GraphPad Prism 7 (GraphPad Software, Inc., California, USA). 
p<0.05 was considered to be statistically significant. Data are presented as the 
mean ± standard deviation. 
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RESULTS 
Photoactivation of Hypericin 
  Hypericin treated cells stimulated with light exhibited a significant dose 
dependant reduction in cell viability as compared to untreated controls (100nM 
Hypericin: HT29 38% cell viability, p=0.0001 and HCT116 34% cell viability, 
p<0.0001), whilst control cultures kept in the dark failed to show any response to 
treatment (100nM Hypericin: HT29 99% cell viability, p=0.33 and HCT116 99% 
cell viability, p=0.18) (Figure 1A and 1B). A similar result was observed when 
HT29 and HCT116 spheroids were subjected to Hypericin-mediated PDT, as 
indicated by increasing propidium iodide fluorescence, which was not apparent in 
control spheroids kept in the dark (Figure 1C). 
 
2D vs. 3D response to Hypericin-PDT 
Both HT29 and HCT116 spheroids were significantly more resistant to 
Hypericin mediated PDT induced cell death as compared to their respective 
monolayer cell cultures. (100nM Hypericin: HT29 spheroids 35% more viable, 
p<0.0001 and HCT116 spheroids are 32% more viable, p=0.01) (Figure 2A & 
2B). 
 
Expression of the ABCG2 protein 
The ABCG2 transmembrane associated protein was observed in both 
HT29 and HCT116 cell lines in 2D cultures, as assessed by immunofluorescence 
(Figures 3A & 3B). Figures 3C and 3D illustrate the distribution of ABCG2 protein 
expression in HT29 and HCT116 spheroids respectively. The protein expression 
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of ABCG2 was most prominent in the outer layers of cells, whereas the core of 
the spheroid had lower levels of expression. On western blot analysis, the protein 
expression of ABCG2 was lower in HCT116 as compared to HT29 2D cultures 
(Figure 3C). There was a significant reduction in ABCG2 protein expression in 
2D as compared to spheroid cultures for both HT29 and HCT116 (Figure 3E & 
3F). Similar to 2D cultures, HCT116 demonstrated lower expression of ABCG2 
protein as compared to HT29 in spheroid cultures. 
 
 
ABCG2 mediated resistance to Hypericin-PDT 
 Figures 4A and 4B show 2D cultures of HT29 and HCT116 cells co-treated 
with 10µM Ko143 (ABCG2 inhibitor) and Hypericin-PDT or Hypericin-PDT alone. 
A significant difference in cell viability was observed in 2D HT29 cells co-treated 
with Ko143 and Hypericin-PDT compared to Hypericin-PDT only treated cells 
(10nM Hypericin: 38% decrease in cell viability, p=0.02). With increasing 
concentrations of Hypericin, the Ko143 co-treated 2D HT29 cells showed a dose 
dependent decrease in cell viability. However, at the higher concentrations of 
Hypericin, there was no difference between the co-treated and Hypericin-PDT 
only cultures (Figure 4A). In 2D HCT116 cultures, no significant difference in cell 
viability was observed between Ko143 treated and untreated samples subjected 
to Hypericin-PDT (p=0.94) (Figure 4B). In spheroid models of both HT29 and 
HCT116 cell lines, a significant difference in cell viability was observed between 
Ko143 and Hypericin-PDT co-treated and Hypericin-PDT alone cell cultures 
(100nM Hypericin: HT29 spheroids 11% less viable, p=0.01 and HCT116 
spheroids 9% less viable, p=0.02) (Figure 4C & 4D). Unlike 2D cultures, the 
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effect of Ko143 on both HT29 and HCT116 spheroid viability was still apparent at 
higher doses of Hypericin-PDT. 
 
Penetration of Hypericin in CRC spheroids 
 Hypericin penetrated through to the central core of both HT29 and HCT116 
spheroids (Figure 5A and 5B). The penetration of Hypericin through the 
spheroids corresponds with the expression of ABCG2 protein. A higher ABCG2 
protein expression in the thicker peripheral layers of proliferating cells in HT29 
spheroids was observed, as compared to HCT116 spheroids (Figure 3C and 3D), 
and may have amounted to the lower retention of Hypericin in the peripheral cell 
layers of HT29 spheroids as compared to HCT116 spheroids (Figure 5). 
 
Re-growth of spheroids following ABCG2 inhibition and Hypericin-PDT 
Twenty-four hours following ABCG2 inhibition and Hypericin-PDT, HT29 and 
HCT116 spheroids had lost their compact spheroidal integrity as indicated by the 
loose cellular debris and loss of structure (Figure 6C). By day 4, spheroids had 
begun to re-form their shapes and continued to increase in volume. By day 10, 
Ko143 and 200nM Hypericin co-treated spheroids were significantly larger as 
compared to the sizes of spheroids on day 0. (HT29 spheroids: 0.22mm3 
increased volume, p<0.005 and HCT116 spheroids: 0.44mm3 increased volume, 
p<0.02) (Figure 6A & 6B). 
 
DISCUSSION 
 Photodynamic therapy is an attractive treatment for solid cancers, which 
can be combined with other therapies and serve as an adjunct to surgical 
excision [29,30]. The clinical application of the first generation of photosensitisers 
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was hampered by unwanted adverse effects, notably photohypersensitivity 
reactions and non-light toxicities [31]. In comparison, Hypericin possesses 
negligible dark toxicity, yet retains a potent phototoxicity, giving it a beneficial 
therapeutic index. 
 
 Many anti-cancer drugs that have shown promise in vitro have 
subsequently failed to achieve their potential in clinical studies. Some of this is 
attributable to the methods used in pre-clinical evaluation. Traditional 2D culture 
models are simplistic representations of cancers in vivo and can give misleading 
results about drug efficacy. In comparison, 3D spheroids are recognised to be 
better models of cancers in vivo and have previously been shown to be useful in 
PDT related studies [32]. Generally, 3D spheroids are more resistant to anti-
cancer treatments, including PDT, as compared to 2D cultures [23,33]. These 
findings have been corroborated by our results as well as other studies 
assessing Hypericin-PDT in 2D and 3D cell cultures [34]. Yang et al. also 
reported an increased resistant to PDT in 3D cultures as compared to 2D models 
of breast cancer when challenged with 5-ALA mediated PDT [35]. Unlike 2D cell 
cultures, where the exposure to PS and light is uniform, the spherical structure of 
spheroids influences the diffusion of the PS and penetration of radiating light. 
This produces a diminishing gradient of PS and light towards the core of the 3D 
structure, simulating in vivo conditions, which, in combination with decreasing 
oxygen tensions, limits the PDT effect in the centre of the spheroid. 3D in vitro 
cancer models therefore fill an essential gap between simple monolayer cell 
cultures and resource intensive and expensive animal models for pre-clinical 
drug evaluation [35].  
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The breast cancer resistance protein also known as ABCG2, is a well-
known member of the ATP-binding cassette (ABC) transporter superfamily [36]. It 
plays a vital role in the uptake, distribution and elimination of xenobiotics and 
other metabolites. ABCG2 has been documented to be over-expressed in 
various cancer cell lines, and can confer resistance to various chemotherapeutics 
by mediating the ATP-dependent efflux of compounds from cells [37,38]. We 
have demonstrated the expression of ABCG2 protein in CRC cell models with an 
upregulation in spheroids, suggesting that adaptive cell signalling pathways exist 
in cancer cells to promote survival [39]. Additionally, we have shown that the 
protein expression of ABCG2 is higher in the outer layers of spheroids as 
compared to the inner and central areas (Figure 3C and 3D). The non-uniformed 
expression of ABCG2 protein in spheroids highlights the physiological advantage 
they possess in providing a better in vitro platform for anti-cancer evaluations. 
The relevance of our in vitro findings to the clinical scenario is evidenced in the 
work of Liu et al. who found ABCG2 to be highly expressed in human colorectal 
cancers as compared to low expression in non-cancer tissue [40]. 
 
Previous studies have shown a correlation between high expression levels 
of ABCG2, low intracellular accumulation of PS and limited PDT effect [41–43]. 
Jendzelovsky et al. identified Hypericin as a preferential substrate for ABCG2 
[44]. When HT29 cells were treated with Hypericin, they showed an increased 
expression in ABCG2 compared to untreated cells, whilst inhibition of ABCG2 
increased the intracellular Hypericin levels. The effect of ABCG2 inhibition on 
intracellular Hypericin accumulation has also been confirmed by others [45]. 
Furthermore, ABCG2 has been implicated in playing a protective role against 
ROS mediated toxicity [46,47]. It therefore appears that ABCG2 is an important 
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mediator of the efficacy of Hypericin-PDT. Our studies have confirmed this in 
CRC models, demonstrating an additive cytotoxic effect when Hypericin-PDT is 
combined with Ko143 inhibition of ABCG2. Similar findings have also been 
reported by others in 2D cultures of oesophageal, bladder, breast, glioblastoma 
and colorectal cancers cell lines [41,48–50]. 
 
We have observed the diffusion of Hypericin through to the core of the 
spheroid models. However, only ~40-50% spheroid cellular death was achieved 
at the highest concentration of Hypericin, when both HT29 and HCT116 
spheroids were co-treated with Hypericin-PDT and Ko143. Oxygen tensions are 
known to vary in spheroids, with decreasing gradients from the outer layers to the 
hypoxic core [51,52]. It is possible that the lack of oxygen in the core could have 
been a limiting factor to the overall cytotoxic effects of PDT in spheroids. 
 
To further highlight the clinical relevance of evaluating PDT in spheroids, 
we observed that both HT29 and HCT116 spheroids had begun to regrow and 
reform their shapes by day 4 after Hypericin-PDT. This highlights the need for 
repeat application of PDT in order to control malignant proliferation and achieve 
effective cancer killing. Such strategies have been developed through the use of 
low dose fractionated PDT, which appears to be more efficacious than single 
dose PDT application [53,54]. 
 
In summary, our studies add to the evidence base about the potential 
application of Hypericin-PDT as an anti-cancer strategy in CRC. We have shown 
that 3D spheroid models of CRC are more resistant to Hypericin-PDT as 
compared to 2D models, which can be overcome, to some extent, by specific 
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inhibition of the ABCG2 transporter. Further research is required to confirm these 
findings in pre-clinical small animal models, but our initial findings offer an 
exciting insight into new strategies for enhancing PDT efficacy in CRC. 
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FIGURES 
 
Figure 1. Light dependant cytotoxicity of Hypericin A) HT29 and B) HCT116 2D cultures were 
incubated with varying concentrations of Hypericin and then irradiated with light or kept in the dark. 
After 24 hours, cell viability was assessed by staining cultures with Propidium Iodide and quantifying 
fluorescence. C) HT29 and HCT116 spheroids were treated with varying concentrations of Hypericin 
+/- light. Spheroids were then stained with Hoechst 33342 (blue fluorescence) and Propidium Iodide 
(red fluorescence) and then imaged. Scalebar = 400μm. Data are shown relative to control treated 
cells and represent means with SD of 3 independent experiments. *p<0.01, **p<0.001, ***p<0.0001. 
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Figure 2. Comparison between 2D and spheroid CRC cell models in response to Hypericin-
PDT. A) HT29 and B) HCT116 2D and spheroid models were incubated with varying concentrations 
of Hypericin and then irradiated with light. After 24 hours, cultures were stained with Propidium 
Iodide and fluorescence was quantified. Data are shown relative to control treated cultures and 
represent means with SD of 3 independent experiments. #p<0.05, *p<0.01, **p<0.001. 
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Figure 3. Expression of ABCG2 protein in 2D and spheroid CRC cell models. A) 2D HT29 B) 
2D HCT116 C) HT29 spheroid sections and D) HCT116 spheroid sections were fixed and incubated 
with a primary anti-BCRP (ABCG2) and secondary Alexa Fluor 488 antibody (Green) and mounted 
with DAPI (Blue). E) Western blot analysis of ABCG2 in protein extracts from 3D spheroid and 2D 
models of HT29 and HCT116 (HepG2 cell lysates served as positive control). F) Quantitative 
analysis of western blots. Data are shown relative to the protein expression of ABCG2 in HepG2 
lysates and represent means with SD of 3 independent experiments. *p<0.01, **p<0.001. 
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Figure 4. Co-treating 2D and spheroid CRC cell models with Ko143 and Hypericin-PDT (HYP-
PDT) A) 2D HT29 B) 2D HCT116 C) HT29 spheroid and D) HCT116 spheroid cultures were co-
treated with varying concentrations of Hypericin and 10μM Ko143 or Hypericin alone and then 
irradiated with light. After 24 hours, cultures were stained with Propidium Iodide and fluorescence 
was quantified. Data are shown relative to control treated cultures and represent means with SD of 
3 independent experiments.  #p<0.05, *p<0.01, **p<0.005. 
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Figure 5. Penetration of Hypericin through CRC spheroid cultures. A) HT29 and B) HCT116 
spheroids were incubated with Hypericin (HYP, Red) for 16 hours. Spheroids were then sectioned, 
mounted with DAPI (Blue) and fluorescently imaged. Scalebar = 100μm. 
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Figure 6. Long-term culture of spheroids following Ko143 and Hypericin-PDT co-treatment 
A) HT29 and B) HCT116 spheroids were incubated with varying concentrations of Hypericin and 
10μM Ko143 and then irradiated with light. Volumes of spheroids were measured for 10 days 
following light radiation. C) Images of 10μM Ko143 treated only and 10μM Ko143 and 200nM 
Hypericin co-treated HT29 and HCT116 spheroids pre-light radiation and at days 0, 1, 4 and 10 
following light irradiation. Scalebar = 400µm. Data shown represents means with SD of 3 
independent experiments. 
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